ATE80043T1 - Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen. - Google Patents

Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.

Info

Publication number
ATE80043T1
ATE80043T1 AT89101237T AT89101237T ATE80043T1 AT E80043 T1 ATE80043 T1 AT E80043T1 AT 89101237 T AT89101237 T AT 89101237T AT 89101237 T AT89101237 T AT 89101237T AT E80043 T1 ATE80043 T1 AT E80043T1
Authority
AT
Austria
Prior art keywords
inflammatory
treatment
disease
salt
acid
Prior art date
Application number
AT89101237T
Other languages
German (de)
English (en)
Inventor
Takahiro Ogawa
Yoshikazu Kuribayashi
Kazumichi Ushio
Akira Ohtori
Original Assignee
Senju Pharma Co
Robins Co Inc A H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11923115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE80043(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senju Pharma Co, Robins Co Inc A H filed Critical Senju Pharma Co
Application granted granted Critical
Publication of ATE80043T1 publication Critical patent/ATE80043T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT89101237T 1988-01-27 1989-01-25 Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen. ATE80043T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1668388 1988-01-27
EP89101237A EP0326915B1 (en) 1988-01-27 1989-01-25 A locally administrable therapeutic composition for inflammatory disease

Publications (1)

Publication Number Publication Date
ATE80043T1 true ATE80043T1 (de) 1992-09-15

Family

ID=11923115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89101237T ATE80043T1 (de) 1988-01-27 1989-01-25 Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.

Country Status (12)

Country Link
US (1) US4910225A (enExample)
EP (1) EP0326915B1 (enExample)
JP (1) JP2683676B2 (enExample)
KR (1) KR960005707B1 (enExample)
AT (1) ATE80043T1 (enExample)
AU (1) AU609932B2 (enExample)
CA (1) CA1325382C (enExample)
DE (1) DE68902649T2 (enExample)
ES (1) ES2052784T3 (enExample)
GR (1) GR3005586T3 (enExample)
HK (1) HK162895A (enExample)
PH (1) PH26827A (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5895645A (en) * 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
RU2116070C1 (ru) * 1996-07-08 1998-07-27 Севиньдж Исмаил кызы Акберова Фармацевтическая композиция
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
DE19961307A1 (de) * 1999-12-18 2001-07-12 Krewel Meuselbach Gmbh Medizinprodukt zur Befeuchtung und Reinigung der Nasenschleimhaut
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
AU2002247284A1 (en) 2001-04-02 2002-10-15 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
KR20040101499A (ko) * 2002-05-03 2004-12-02 알콘, 인코퍼레이티드 암페낙 또는 네파페낙을 이용한 혈관 내피 성장 인자 매개혈관 장애 치료 방법
US8129431B2 (en) * 2003-01-21 2012-03-06 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
WO2004112772A1 (en) * 2003-06-13 2004-12-29 Alcon, Inc. Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
WO2005046700A1 (ja) * 2003-11-14 2005-05-26 Senju Pharmaceutical Co., Ltd. アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤
FR2876581B1 (fr) * 2004-10-20 2007-05-18 Interpharm Dev Composition bioadhesive a liberation programmee
WO2006049250A1 (ja) 2004-11-05 2006-05-11 Senju Pharmaceutical Co., Ltd. 眼内移行性促進水性点眼剤
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
WO2006121964A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
CA2607608A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20090010850A1 (en) * 2007-05-24 2009-01-08 Ousler Iii George W Formulations and methods for treating dry eye
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
UY31058A1 (es) * 2007-05-01 2008-10-31 Alcon Res Ltd Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
RU2010138799A (ru) * 2008-02-21 2012-03-27 Иста Фармасьютикалз (Us) Офтальмологические нестероидные противовоспалительные средства в качестве адъювантов
US8778999B2 (en) * 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
MX341189B (es) 2011-01-18 2016-08-09 Senju Pharma Co Composicion liquida y acousa de bromfenaco, que tiene efectividad conservadora.
HK1208162A1 (en) 2012-05-03 2016-02-26 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
PL2919755T3 (pl) 2012-11-19 2018-07-31 Bausch & Lomb Incorporated Wodna ciekła kompozycja zawierająca kwas 2-amino-3-(4-bromobenzoilo)fenylooctowy
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN107915751A (zh) 2013-02-20 2018-04-17 卡拉制药公司 治疗性化合物和其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US20160143869A1 (en) 2013-06-19 2016-05-26 Sentiss Research Center Stable bromfenac solution
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US20170000889A1 (en) 2013-12-12 2017-01-05 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
CN106404952B (zh) * 2016-08-31 2019-06-11 辰欣佛都药业（汶上）有限公司 一种溴芬酸钠滴眼液有关物质的测定方法
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
KR20200099547A (ko) * 2017-12-14 2020-08-24 산텐 세이야꾸 가부시키가이샤 2-아미노-3-(4-브로모벤조일)페닐아세트산 또는 그의 염을 함유하는 점안제
CN116490211A (zh) 2020-10-29 2023-07-25 株式会社泰俊制药 眼用组合物
JP2024504980A (ja) 2021-01-21 2024-02-02 テジュン ファーマシューティカル カンパニー リミテッド 点眼組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577461A5 (enExample) * 1975-08-13 1976-07-15 Robins Co Inc A H
AU512570B2 (en) * 1975-08-13 1980-10-16 A.H. Robins Company, Incorporated Amino benzophenones
JPS58201710A (ja) * 1982-05-18 1983-11-24 Meiji Seika Kaisha Ltd 口腔内用抗炎症ペ−スト剤
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters

Also Published As

Publication number Publication date
KR890011823A (ko) 1989-08-22
JP2683676B2 (ja) 1997-12-03
EP0326915B1 (en) 1992-09-02
CA1325382C (en) 1993-12-21
DE68902649D1 (de) 1992-10-08
EP0326915A1 (en) 1989-08-09
JPH02124817A (ja) 1990-05-14
AU2878689A (en) 1989-07-27
KR960005707B1 (ko) 1996-05-01
PH26827A (en) 1992-11-05
HK162895A (en) 1995-10-27
GR3005586T3 (enExample) 1993-06-07
AU609932B2 (en) 1991-05-09
DE68902649T2 (de) 1993-02-11
US4910225A (en) 1990-03-20
ES2052784T3 (es) 1994-07-16

Similar Documents

Publication Publication Date Title
DE68902649D1 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
NO912410L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocyklen-derivater.
KR900015722A (ko) N-(3,4-디메톡시신나모일) 안트라닐산을 함유하는 약제 조성물
ATE287212T1 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
BR0014179A (pt) Modernos derivados de ácido aminodicarboxìlico com propriedades farmacêuticas
KR880000091A (ko) 국소용 약제학적 조성물 이의 제조방법 및 이의 용도
BRPI0210707B8 (pt) composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
RU99121654A (ru) Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
JPS6410500B2 (enExample)
KR930019224A (ko) 유산 위험 치료제
DE3750464D1 (de) Pharmazeutisches Präparat zur Behandlung des Katarakts.
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
KR870006035A (ko) 신규 항균제 1-티에닐-4-옥소퀴놀린-3-카복실산 화합물의 제법
ATE73330T1 (de) Verwendung von pharmaceutischen zusammensetzungen fuer die herstellung von arzneimitteln fuer die behandlung psychiatrischer stoerungen.
ATE428412T1 (de) Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
EP1325918A4 (en) INHIBITORS OF CARDIAC MUSCLE CELL APOPTOSIS AND THERAPEUTIC / PROPHYLACTIC AGENTS AGAINST HEART DISEASE
RU2073523C1 (ru) Препарат для лечения ожоговой болезни глаз i-iy степеней
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
DE3884878D1 (de) Uricosuretische Zusammensetzung.
RU93032703A (ru) Способ лечения острых респираторных заболеваний

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time